Black Diamond Therapeutics (BDTX) closed at $2.08 on October 22, 2026, unchanged from the previous close, on volume of 779,241 shares (30-day average 735,198).
Data as of October 22, 2026.
22-Oct-2026
Globe Newswire (Wed, 2-Sep 4:01 PM ET)
Globe Newswire (Wed, 5-Aug 4:01 PM ET)
BDTX Phase 2 Silevertinib Results Update Scheduled—Key Milestone Approaches for EGFRm NSCLC Therapy
Market Chameleon (Wed, 20-May 6:32 AM ET)
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
Black Diamond Therapeutics trades on the NASDAQ stock market under the symbol BDTX.
As of October 22, 2026, BDTX stock price was flat at $2.08 with 779,241 million shares trading.
BDTX has a beta of 2.32, meaning it tends to be more sensitive to market movements. BDTX has a correlation of 0.17 to the broad based SPY ETF.
BDTX has a market cap of $119.16 million. This is considered a Micro Cap stock.
Last quarter Black Diamond Therapeutics reported $0 in Revenue and -$.17 earnings per share. This fell short of revenue expectation by $-30 million and exceeded earnings estimates by $.03.
In the last 3 years, BDTX traded as high as $7.66 and as low as $1.20.
The top ETF exchange traded funds that BDTX belongs to (by Net Assets): VTI, IWM, FESM, DFSV, SMLF.
BDTX has underperformed the market in the last year with a return of -44.7%, while SPY returned +15.5%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in BDTX shares. However, BDTX has outperformed the market in the last 3 month and 2 week periods, returning +13.7% and +14.9%, while SPY returned +2.5% and -1.3%, respectively. This indicates BDTX has been having a stronger performance recently.
BDTX support price is $2.00 and resistance is $2.17 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BDTX shares will trade within this expected range on the day.
